Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,903 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status.
Westermann F, Henrich KO, Wei JS, Lutz W, Fischer M, König R, Wiedemeyer R, Ehemann V, Brors B, Ernestus K, Leuschner I, Benner A, Khan J, Schwab M. Westermann F, et al. Among authors: schwab m. Clin Cancer Res. 2007 Aug 15;13(16):4695-703. doi: 10.1158/1078-0432.CCR-06-2818. Epub 2007 Jul 25. Clin Cancer Res. 2007. PMID: 17652624
Genetic parameters of neuroblastomas.
Westermann F, Schwab M. Westermann F, et al. Among authors: schwab m. Cancer Lett. 2002 Oct 28;184(2):127-47. doi: 10.1016/s0304-3835(02)00199-4. Cancer Lett. 2002. PMID: 12127685 Review.
Regulation of BIRC5 and its isoform BIRC5-2B in neuroblastoma.
Eckerle I, Muth D, Batzler J, Henrich KO, Lutz W, Fischer M, Witt O, Schwab M, Westermann F. Eckerle I, et al. Among authors: schwab m. Cancer Lett. 2009 Nov 18;285(1):99-107. doi: 10.1016/j.canlet.2009.05.007. Epub 2009 Jun 3. Cancer Lett. 2009. PMID: 19497660
Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma.
Muth D, Ghazaryan S, Eckerle I, Beckett E, Pöhler C, Batzler J, Beisel C, Gogolin S, Fischer M, Henrich KO, Ehemann V, Gillespie P, Schwab M, Westermann F. Muth D, et al. Among authors: schwab m. Cancer Res. 2010 May 1;70(9):3791-802. doi: 10.1158/0008-5472.CAN-09-1245. Epub 2010 Apr 27. Cancer Res. 2010. PMID: 20424123
Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.
Oberthuer A, Juraeva D, Hero B, Volland R, Sterz C, Schmidt R, Faldum A, Kahlert Y, Engesser A, Asgharzadeh S, Seeger R, Ohira M, Nakagawara A, Scaruffi P, Tonini GP, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Vandesompele J, Speleman F, Noguera R, Piqueras M, Bénard J, Valent A, Avigad S, Yaniv I, Grundy RG, Ortmann M, Shao C, Schwab M, Eils R, Simon T, Theissen J, Berthold F, Westermann F, Brors B, Fischer M. Oberthuer A, et al. Among authors: schwab m. Clin Cancer Res. 2015 Apr 15;21(8):1904-15. doi: 10.1158/1078-0432.CCR-14-0817. Epub 2014 Sep 17. Clin Cancer Res. 2015. PMID: 25231397
MYCN/MYC-mediated drug resistance mechanisms in neuroblastoma.
Gogolin S, Dreidax D, Becker G, Ehemann V, Schwab M, Westermann F. Gogolin S, et al. Among authors: schwab m. Int J Clin Pharmacol Ther. 2010 Jul;48(7):489-91. doi: 10.5414/cpp48489. Int J Clin Pharmacol Ther. 2010. PMID: 20557856 No abstract available.
1,903 results